Literature DB >> 2554521

A second plasma inhibitor of activated protein C: alpha 1-antitrypsin.

F J van der Meer1, N H van Tilburg, A van Wijngaarden, I K van der Linden, E Briët, R M Bertina.   

Abstract

Inactivation of activated protein C (APC) in normal human plasma was studied in the absence and presence of heparin. In the absence of heparin APC inactivation followed pseudo-first order kinetics. In the presence of heparin the neutralization of APC was found to be biphasic. Up to 500 nM APC could be readily inactivated in normal plasma, indicating that the concentration of the APC inhibitor must be higher than previously assumed. Plasma deficient in the protein C inhibitor (PCI-I, as described by Suzuki and coworkers) and deficient in beta 2-glycoprotein I still possessed APC neutralizing capacity, presumably through the formation of complexes of APC with another plasma protein as was demonstrated by immunoblotting with anti-protein C antibodies. Together these data made us to conclude that a second inhibitor of APC (PCI-II) must be present in normal human plasma. This second inhibitor should be heparin independent, have a relatively high plasma concentration and form complexes with APC. Subsequently, we purified this PCI-II by isolating APC-PCI-II complexes from plasma deficient of vitamin K dependent proteins, PCI-I and beta 2-glycoprotein-I, to which purified human APC had been added. Purified PCI-II has a molecular weight of 50,000 daltons and aminoacid analysis revealed that PCI-II is identical with alpha 1-antitrypsin (alpha 1-AT). The second order rate constant for the reaction between purified alpha 1-AT and APC was found to be 269 M-1 min-1 in the absence of calcium and 602 M-1 min-1 in the presence of calcium.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554521

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

Review 1.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

2.  Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro.

Authors:  D M Keeling; A J Wilson; I J Mackie; D A Isenberg; S J Machin
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

3.  Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.

Authors:  S R Cai; S C Kennedy; W M Bowling; M W Flye; K P Ponder
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

4.  Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

Authors:  Rolf Burghaus; Katrin Coboeken; Thomas Gaub; Lars Kuepfer; Anke Sensse; Hans-Ulrich Siegmund; Wolfgang Weiss; Wolfgang Mueck; Joerg Lippert
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

5.  Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19.

Authors:  Aurélien Philippe; Mathilde Puel; Céline Narjoz; Nicolas Gendron; Marie Agnès Durey-Dragon; Benoit Vedie; Malika Balduyck; Richard Chocron; Caroline Hauw-Berlemont; Olivier Sanchez; Tristan Mirault; Jean-Luc Diehl; David M Smadja; Marie Anne Loriot
Journal:  Biochimie       Date:  2022-08-08       Impact factor: 4.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.